

NIH funding opportunities

11 March 2024 (#10)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-AG-24-004](#) U.S. Health in the International Perspective. This NOSI expresses National Institute on Aging ([NIA](#)) interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. The complex, multifactorial pathways across the life course leading to these proximate causes of death warrant further investigation. This NOSI encourages research that leverages differences between macro- and meso-level social and environmental factors at the country, region, and/or state-level to elucidate. This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 8, 2027.

[NOT-AT-24-035](#) Interventions to Reduce Chronic Inflammation and Inflammation-Related Morbidity in People Living with HIV/AIDS. The National Center for Complementary and Integrative Health ([NCCIH](#)) and other participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are soliciting projects to evaluate and elucidate interventions to prevent, reduce, and/or reverse chronic systemic inflammation and inflammation-related comorbidities and complications in people living with HIV/AIDS (PWH). The main objective of this NOSI is to encourage applications for clinical and basic and mechanistic research to develop, refine, and/or test interventions that reduce or prevent chronic HIV-associated inflammation, and evaluate whether this ultimately reduces the sequelae of that inflammation. This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 13, 2024.

[NOT-CA-24-037](#) Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk. The purpose of this notice of special interest (NOSI) is to solicit submission of innovative epidemiologic research designed and focused on facilitating and enhancing our understanding of the impact of long-term incretin mimetic use on cancer risk and outcomes among individuals with and without comorbid conditions. Cancer types vary in latency after exogenous exposure(s). As such, latency/temporal issues (long term exposure to incretin mimetics and follow-up time) must be critically considered in proposed projects. A minimum latency period for incretin mimetic use of one (1) year is required. In this NOSI we seek applications using large clinical data sets. Investigators are strongly encouraged to use one of various epidemiologic study designs in response to this NOSI. These may include leveraging existing population-based data sources, such as cohorts and registries, and data from available randomized clinical trials. Applicants are also encouraged to incorporate real-world data (e.g., electronic health records) when possible, or may propose new data collection as warranted. This NOSI expires May 09, 2026.

Notice of Funding Opportunity (NOFO)

1. **[RFA-AT-24-008](#) Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01 Clinical Trial Not Allowed).** This NOFO will support development, adaptation, and/or applications of computational tools to aggregate and analyze orthogonal chemical and/or biological data sets related to natural products with the aim of generating novel testable hypotheses regarding their biological activity and role in the context of whole person health research. Projects must leverage and merge multiple compatible or interoperable sources and/or types of data. Use of artificial intelligence and machine learning approaches is encouraged. This NOFO is part of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include the Botanical Dietary Supplements Translational Research Teams (RM1) and [RFA-AT-24-007](#) Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24).

Due dates: June 28, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are limited to less than \$500K in Direct Costs but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

2. **[RFA-FD-24-037](#) Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional.** The purpose of this notice of funding opportunity (NOFO) is to address topics related to the use of digital health technologies (DHTs) for remote data acquisition in clinical investigations to support drug development.

Due dates: May 20, 2024. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: FDA/ CDER intends to commit \$1.1 million in fiscal year 2024 and \$860,000 in 2025 to fund 1 (one) award. The scope of the proposed project should determine the project period. The maximum project period is 2 (two) years.

<p>Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 Kth Floor, Teaching Block, Tygerberg Campus.</p>	<p>Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street</p>
<p>Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za</p>	<p>Enquiries: research@sun.ac.za</p>
<p>Add “Interest in NIH opportunity” in the subject line. Add the notice number in the text of the email.</p>	